180 related articles for article (PubMed ID: 28094179)
1. Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors.
Boucle S; Lu X; Bassit L; Ozturk T; Russell OO; Amblard F; Coats SJ; Schinazi RF
Bioorg Med Chem Lett; 2017 Feb; 27(4):904-910. PubMed ID: 28094179
[TBL] [Abstract][Full Text] [Related]
2. The Heteroaryldihydropyrimidine Bay 38-7690 Induces Hepatitis B Virus Core Protein Aggregates Associated with Promyelocytic Leukemia Nuclear Bodies in Infected Cells.
Huber AD; Wolf JJ; Liu D; Gres AT; Tang J; Boschert KN; Puray-Chavez MN; Pineda DL; Laughlin TG; Coonrod EM; Yang Q; Ji J; Kirby KA; Wang Z; Sarafianos SG
mSphere; 2018 Apr; 3(2):. PubMed ID: 29669885
[TBL] [Abstract][Full Text] [Related]
3. A new series of HAPs as anti-HBV agents targeting at capsid assembly.
Yang XY; Xu XQ; Guan H; Wang LL; Wu Q; Zhao GM; Li S
Bioorg Med Chem Lett; 2014 Sep; 24(17):4247-9. PubMed ID: 25127104
[TBL] [Abstract][Full Text] [Related]
4. Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
Ren Q; Liu X; Luo Z; Li J; Wang C; Goldmann S; Zhang J; Zhang Y
Bioorg Med Chem; 2017 Feb; 25(3):1042-1056. PubMed ID: 28082068
[TBL] [Abstract][Full Text] [Related]
5. Novel non-heteroarylpyrimidine (HAP) capsid assembly modifiers have a different mode of action from HAPs in vitro.
Corcuera A; Stolle K; Hillmer S; Seitz S; Lee JY; Bartenschlager R; Birkmann A; Urban A
Antiviral Res; 2018 Oct; 158():135-142. PubMed ID: 30031759
[TBL] [Abstract][Full Text] [Related]
6. Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly.
Toyama M; Sakakibara N; Takeda M; Okamoto M; Watashi K; Wakita T; Sugiyama M; Mizokami M; Ikeda M; Baba M
Virus Res; 2019 Oct; 271():197677. PubMed ID: 31376401
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of aminothiazole based Hepatitis B Virus (HBV) capsid inhibitors.
Pan T; Ding Y; Wu L; Liang L; He X; Li Q; Bai C; Zhang H
Eur J Med Chem; 2019 Mar; 166():480-501. PubMed ID: 30739828
[TBL] [Abstract][Full Text] [Related]
8. Design, diversity-oriented synthesis and biological evaluation of novel heterocycle derivatives as non-nucleoside HBV capsid protein inhibitors.
Jia H; Yu J; Du X; Cherukupalli S; Zhan P; Liu X
Eur J Med Chem; 2020 Sep; 202():112495. PubMed ID: 32712535
[TBL] [Abstract][Full Text] [Related]
9. In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations.
Wang XY; Wei ZM; Wu GY; Wang JH; Zhang YJ; Li J; Zhang HH; Xie XW; Wang X; Wang ZH; Wei L; Wang Y; Chen HS
Antivir Ther; 2012; 17(5):793-803. PubMed ID: 22668794
[TBL] [Abstract][Full Text] [Related]
10. Study on 2-arylthio-5-iodo pyrimidine derivatives as novel nonnucleoside inhibitors against hepatitis B virus DNA replication.
Zhao J; Tu J; Fan N; Chen X; Lu F; Zhang Y; Zhang L; Tian C; Zhang Z; Liu J; Wang X
Future Med Chem; 2016 May; 8(7):751-63. PubMed ID: 27172826
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors.
Ma Y; Zhao S; Ren Y; Cherukupalli S; Li Q; Woodson ME; Bradley DP; Tavis JE; Liu X; Zhan P
Eur J Med Chem; 2021 Dec; 225():113780. PubMed ID: 34438123
[TBL] [Abstract][Full Text] [Related]
12. Discovery of (1
Wang C; Pei Y; Wang L; Li S; Jiang C; Tan X; Dong Y; Xiang Y; Ma Y; Liu G
J Med Chem; 2020 Jun; 63(11):6066-6089. PubMed ID: 32421339
[TBL] [Abstract][Full Text] [Related]
13. Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly.
Wu G; Liu B; Zhang Y; Li J; Arzumanyan A; Clayton MM; Schinazi RF; Wang Z; Goldmann S; Ren Q; Zhang F; Feitelson MA
Antimicrob Agents Chemother; 2013 Nov; 57(11):5344-54. PubMed ID: 23959305
[TBL] [Abstract][Full Text] [Related]
14. Influences on viral replication and sensitivity to GLS4, a HAP compound, of naturally occurring T109/V124 mutations in hepatitis B virus core protein.
Wang J; Zhang H; Zhang Y; Jiang D; Li J; Goldmann S; Ren Q; Fei R; Wang X; Wei L
J Med Virol; 2017 Oct; 89(10):1804-1810. PubMed ID: 28401569
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of hepatitis B virus replication by N-hydroxyisoquinolinediones and related polyoxygenated heterocycles.
Edwards TC; Lomonosova E; Patel JA; Li Q; Villa JA; Gupta AK; Morrison LA; Bailly F; Cotelle P; Giannakopoulou E; Zoidis G; Tavis JE
Antiviral Res; 2017 Jul; 143():205-217. PubMed ID: 28450058
[TBL] [Abstract][Full Text] [Related]
16. BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly.
Stray SJ; Zlotnick A
J Mol Recognit; 2006; 19(6):542-8. PubMed ID: 17006877
[TBL] [Abstract][Full Text] [Related]
17. Optimization and Synthesis of Pyridazinone Derivatives as Novel Inhibitors of Hepatitis B Virus by Inducing Genome-free Capsid Formation.
Lu D; Liu F; Xing W; Tong X; Wang L; Wang Y; Zeng L; Feng C; Yang L; Zuo J; Hu Y
ACS Infect Dis; 2017 Mar; 3(3):199-205. PubMed ID: 27989113
[TBL] [Abstract][Full Text] [Related]
18. Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2'-deoxyribose, on wild-type and mutant hepatitis B virus replication.
Kumar R; Semaine W; Johar M; Tyrrell DL; Agrawal B
J Med Chem; 2006 Jun; 49(12):3693-700. PubMed ID: 16759112
[TBL] [Abstract][Full Text] [Related]
19. Exploring the binding mechanism of Heteroaryldihydropyrimidines and Hepatitis B Virus capsid combined 3D-QSAR and molecular dynamics.
Tu J; Li JJ; Shan ZJ; Zhai HL
Antiviral Res; 2017 Jan; 137():151-164. PubMed ID: 27908829
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Novel Pyrimidine-Based Capsid Assembly Modulators as Potent Anti-HBV Agents.
Kim W; Kang JA; Park M; Jeong PH; Kim YJ; Cho Y; Park SG; Kim YC
J Med Chem; 2021 May; 64(9):5500-5518. PubMed ID: 33887912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
